The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 2, 2011, Pages 219-227

  Yu, Jingping ^a,b   Liu, Fenju ^a   Sun, Zhiqiang ^b   Sun, Meiling ^a   Sun, Suping ^b  

^a SOOCHOW UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

cell cycle; cell proliferation; radiosensitivity; TE1 cells; thalidomide; vascular endothelial growth factor

Indexed keywords

MESSENGER RNA; THALIDOMIDE; VASCULOTROPIN;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOSENSITIVITY; X RAY;

APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL SURVIVAL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; RADIATION TOLERANCE; RNA, MESSENGER; THALIDOMIDE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; X-RAYS;

EID: 79955906517     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0897     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74.
2. Yang L, Li LD, Chen YD. Cancer incidence and mortality estimates and prediction for year 2000 and 2005 in China. Chin J Health Stat 2005;22:219.
3. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: Role of surgery and other modalities. Lancet Oncol 2007;8:545.
4. Delcambre C, Jacob JH, Pottier D, et al. Localized squamouscell cancer of the esophagus: Retrospective analysis of three treatment schedules. Radiother Oncol 2001;59:195.
5. Shi XH, Yao W, Liu T. Late course accelerated fractionation in radiotherapy of esophageal carcinoma. Radiother Oncol 1999;51:21.
6. Zhao KL, Shi XH, Jiang GL, et al. Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy for squamous cell carcinoma of the esophagus: A phase III randomized study. Int J Radiat Oncol Biol Phys 2005;62:1014.
7. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01).Radiation Therapy Oncology Group. JAMA 1999;281:1623.
8. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combinedmodality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167.
9. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310.
10. Xiao ZF, Yang ZY, Miao YJ, et al. Influence of number of metastatic lymph nodes on survival of curative resected thoracic esophageal cancer patients and value of radiotherapy: Report of 549 cases. Int J Radiat Oncol Biol Phys 2005;62:82.
11. Solberg TD, Nearman J, Mullins J, et al. Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:918.
12. Kerbel RS, Viloria-Petit A, Okada F, et al. Establishing a link between oncogenes and tumor angiogenesis. Mol Med 1998; 4:286.
13. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527.
14. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).J Cell Mol Med 2005;9:777.
15. Carmeliet P, Collen D. Molecular basis of angiogenesis. Role of VEGF and VE-cadherin. Ann N Y Acad Sci 2000;902:249.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27.
17. Ding MX, Lin XQ, Fu XY, et al. Expression of vascular endothelial growth factor-C and angiogenesis in esophageal squamous cell carcinoma. World J Gastroenterol 2006;12: 4582.
18. Mobius C, Freire J, Becker I, et al. VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg 2007;31:1768.
19. Han U, Can OI, Han S, et al. Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma? Dis Esophagus 2007;20:379.
20. Choi JY, Jang KT, Shim YM, et al. Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: Comparison with positron emission tomography. Ann Surg Oncol 2006;13:1054.
21. Noguchi T, Takeno S, Shibata T, et al. VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol Rep 2002;9:995.
22. Matsumoto M, Natsugoe S, Okumura H, et al. Overexpression of vascular endothelial growth factor-C correlates with lymph node micrometastasis in submucosal esophageal cancer. J Gastrointest Surg 2006;10:1016.
23. Rades D, Golke H, Schild SE, et al. Impact of VEGF and VEGF receptor 1 (FLT1) expression on the prognosis of stage III esophageal cancer patients after radiochemotherapy. Strahlenther Onkol 2008;184:416.
24. Langeland Marthinsen AB, Dybdahl Wanderas A, Lundgren S, et al. Effects of growth factors on growth and radiation sensitivity of the human breast cancer cell line T-47D. Oncol Rep 2002;9:397.
25. Hovinga KE, Stalpers LJ, van Bree C, et al. Radiationenhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines-a clue to radioresistance? J Neurooncol 2005;74:99.
26. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 2008;7:1152.
27. Amato RJ. Thalidomide: An antineoplastic agent. Curr Oncol Rep 2002;4:56.
28. Yata K, Otsuki T, Kurebayashi J, et al. Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells. Int J Oncol 2003;22: 165.
29. Teo SK. Properties of thalidomide and its analogues: Implications for anticancer therapy. AAPS J 2005;7:E14.
30. Fujita Y, Abe R, Shimizu H. Clinical approaches toward tumor angiogenesis: Past, present and future. Curr Pharm Des 2008;14:3820.
31. Jagannath S. Current standards for first-line therapy of multiple myeloma. Clin Lymphoma Myeloma 2007; 7(suppl5):S207.
32. Vaishampayan UN, Heilbrun LK, Marsack C, et al. Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anticancer Drugs 2007;18:1221.
33. Pujol JL, Breton JL, Gervais R, et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: An intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 2007;25:3945.
34. Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol 2009;2:161.
35. Kraemer A, Hauser S, Kim Y, et al. Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. Ger Med Sci 2009;7:Doc04.
36. Kozin SV, Boucher Y, Hicklin DJ, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001;61:39.
37. Zips D, Krause M, Hessel F, et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 2003;23:3869.
38. McDonnell CO, Holden G, Sheridan ME, et al. Improvement in efficacy of chemoradiotherapy by addition of an antiangiogenic agent in a murine tumor model. J Surg Res 2004;116:19.
39. Ning S, Laird D, Cherrington JM, et al. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002;157:45.
40. Greco O, Marples B, Dachs GU, et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther 2002;9:1403.
41. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374.
42. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11:743.
43. Epperly MW, Greenberger EE, Franicola D, et al. Thalidomide radiosensitization of normal murine hematopoietic but not squamous cell carcinoma or multiple myeloma tumor cell lines. In Vivo 2006;20:333.
44. Marriott JB, Clarke IA, Czajka A, et al. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. Cancer Res 2003; 63:593.
45. Ng SS, Gutschow M, Weiss M, et al. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 2003;63:3189.
46. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943.
47. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6:2166.